The role of nonrandomized trials in the evaluation of oncology drugs

Optimizing Dosing of Oncology Drugs

(2014) L Minasian et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

(2013) M. Axelson et al.   CLINICAL CANCER RESEARCH

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009

(2012) F. Janku et al.   CLINICAL CANCER RESEARCH

Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies

(2012) Rajul K. Jain et al.   JOURNAL OF CLINICAL ONCOLOGY

When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

(2012) G. R. Oxnard et al.   JNCI-Journal of the National Cancer Institute

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

(2012) Beth Sherrill et al.   OncoTargets and Therapy

Accelerated Approval of Oncology Products: The Food and Drug Administration Experience

(2011) John R. Johnson et al.   JNCI-Journal of the National Cancer Institute

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Role of randomized phase III trials in an era of effective targeted therapies

(2011) Manish R. Sharma et al.   Nature Reviews Clinical Oncology

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

(2008) M. C. Heinrich et al.   CLINICAL CANCER RESEARCH

Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?

(2008) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer: The Road to Amiens

(2008) David J. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY